HighTide Therapeutics Inc (2511.HK)
HKD 1.11
(14.43%)
HKD 1.11
(14.43%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.02 Million CNY | -36.42% |
| 2022 | -1.48 Million CNY | 22.69% |
| 2021 | -1.91 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -3.12 Million HKD | 0.0% |
| 2024 Q1 | - HKD | 100.0% |
| 2023 Q1 | - HKD | 100.0% |
| 2023 Q4 | -1.09 Million HKD | 0.0% |
| 2023 Q3 | - HKD | 100.0% |
| 2023 Q2 | -923.98 Thousand HKD | 0.0% |
| 2023 FY | -2.02 Million CNY | -36.42% |
| 2022 Q2 | -652.06 Thousand HKD | 0.0% |
| 2022 FY | -1.48 Million CNY | 22.69% |
| 2022 Q4 | -823.6 Thousand HKD | 0.0% |
| 2021 FY | -1.91 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 392.81 Million HKD | 100.514% |
| CK Life Sciences Int'l., (Holdings) Inc. | 947.7 Million HKD | 100.213% |